According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:
- Zenrelia, a once-daily oral Janus kinase (“JAK”) inhibitor for canine dermatology, was less safe than Elanco had led investors to believe;
- Elanco was unlikely to meet its own previously issued timeline for the U.S. approval and commercial launch of both Zenrelia and Credelio Quattro, a broad spectrum parasiticide product for dogs;
- accordingly, Elanco’s business and/or financial prospects were overstated; and
- as a result, Elanco’s public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
